Atazanavir contraindications

Jump to navigation Jump to search
Atazanavir
REYATAZ® FDA Package Insert
Description
Clinical Pharmacology
Microbiology
Indications and Usage
Contraindications
Warnings and Precautions
Adverse Reactions
Overdosage
Dosage and Administration
How Supplied
Labels and Packages

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mohamed Moubarak, M.D. [2]

Contraindications

REYATAZ (atazanavir sulfate) is contraindicated:

  • in patients with previously demonstrated clinically significant hypersensitivity (eg, Stevens-Johnson syndrome, erythema multiforme, or toxic skin eruptions) to any of the components of this product.
  • when coadministered with drugs that are highly dependent on CYP3A or UGT1A1 for clearance, and for which elevated plasma concentrations are associated with serious and/or life-threatening events. These and other contraindicated drugs are listed in Table 3.[1]


References

  1. "REYATAZ (ATAZANAVIR SULFATE) CAPSULE, GELATIN COATED [E.R. SQUIBB & SONS, L.L.C.]". Text " accessdate" ignored (help)

Adapted from the FDA Package Insert.